Galle Liz Insider Trades

Insider Trading History

Track insider trading activity for Galle Liz. See latest buy and sell transactions across all companies.

Holdings

Company
Holding Value
Last Transaction
Sale/Purchase
Amount
Price
Current Price

Insider Trades History

Company
Holding Value
Last Transaction
Sale/Purchase
Amount
Price
Current Price
CVRx
CVRx CVRX
VP OF GLOBAL CLINICAL RESEARCH
Holding Value $0 0 shares
Last Trade
Oct 16, 2023 Sale (Option Exercise)Shares acquired or sold by exercising stock options or converting another derivative security.
$9.6k 778 shares
$12.34
$5.39
CVRx
CVRx CVRX
VP OF GLOBAL CLINICAL RESEARCH
Holding Value $4.19k 778 shares
Last Trade
Oct 16, 2023 Purchase (Option Exercise)Shares acquired or sold by exercising stock options or converting another derivative security.
$9.6k 778 shares
$12.34
$5.39
CVRx
CVRx CVRX
Director, VP OF GLOBAL CLINICAL RESEARCH
Holding Value $140k 26,000 shares
Last Trade
Jan 18, 2023 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$396k 26,000 shares
$15.22
$5.39
CVRx
CVRx CVRX
Director, VP OF GLOBAL CLINICAL RESEARCH
Holding Value $43.1k 8,000 shares
Last Trade
Aug 02, 2022 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$72.1k 8,000 shares
$9.01
$5.39
CVRx
CVRx CVRX
VP Of Global Clinical Research
Holding Value $140k 25,900 shares
Last Trade
Jan 18, 2022 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$235k 25,900 shares
$9.08
$5.39
CVRx
CVRx CVRX
VP Of Global Clinical Research
Holding Value $0 0 shares
Last Trade
Jun 29, 2021 Sale
No data
No data
$5.39
CVRx
CVRx CVRX
VP Of Global Clinical Research
Holding Value $106k 19,700 shares
Last Trade
Jun 29, 2021 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
No data
No data
$5.39

See more insider trades for free

Join Stockcircle to see more insider trades and be the first to know about new executive transactions.

Sign Up